Patent · US Active

ADAMTS-13 mutant

US9109217B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE · JP

Inventor

Kenji Soejima · Kikuchi, JP

Key dates

Filing date	Oct 30, 2014
Grant date	Aug 18, 2015
Priority date	—
Expiry date	Oct 30, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/24087
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.